Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 53-56

  Komiya, Akira ^a   Yasuda, Kenji ^a   Nozaki, Tetsuo ^a   Fujiuchi, Yasuyoshi ^a   Hayashi, Shin Ichi ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chemotherapy; High dose rate brachytherapy; Neuroendocrine differentiation; Neuron specific enolase; Prostate cancer; Radiation therapy; Small cell carcinoma

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; IRIDIUM 192; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN;

AGED; ANEMIA; ANOREXIA; ARTICLE; BIOPSY; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; DIGITAL RECTAL EXAMINATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENZYME BLOOD LEVEL; GENERAL CONDITION; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; IMPLANT; LEUKOPENIA; LUNG LESION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MICTURITION DISORDER; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PELVIS LYMPH NODE; PROSTATE; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RISK; SIDE EFFECT; SMALL CELL CARCINOMA; STOMACH ULCER; SWELLING; TRANSRECTAL ULTRASONOGRAPHY; TUMOR CELL; URETHRA STENOSIS; URETHROSCOPY;

EID: 84869078646     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.998     Document Type: Article

References (23)

1. Abrahamsson PA, Wadström LB, Alumets J, et al: Peptide-hormone-and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 182: 298-307, 1987.
2. Komiya A, Suzuki H, Imamoto T, et al: Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 16: 37-44, 2009.
3. Cussenot O, Villette JM, Cochand-Priollet B and Berthon P: Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 8: 43-51, 1998.
4. Weaver MG, Abdul-Karim FW and Srigley JR: Paneth cell-like change and small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol 16: 1013-1016, 1992.
5. Helpap B and Köllermann J: Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434: 385-391, 1999.
6. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 70 (1 Suppl): 254-268, 1992.
7. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A and Dexeus FH: Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147: 935-937, 1992.
8. Sella A, Konichezky M, Flex D, Sulkes A and Baniel J: Low PSA metastatic androgen-independent prostate cancer. Eur Urol 38: 250-254, 2000.
9. Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 147: 804-807, 1992.
10. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y and Hosaka M: Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 88: 982-983, 2001.
11. Tanaka M, Suzuki Y, Takaoka K, et al: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 8: 431-436, 2001.
12. Hvamstad T, Jordal A, Hekmat N, Paus E and Fosså SD: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 44: 215-221, 2003.
13. Deng X, Liu H, Huang J, et al: Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68: 9663-9670, 2008.
14. Deng X, Elzey BD, Poulson JM, et al: Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells invitro, invivo and in prostate cancer patients. Am J Cancer Res 1: 834-844, 2011.
15. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998.
16. Asmis TR, Reaume MN, Dahrouge S and Malone S: Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97: 711-715, 2006.
17. Yao JL, Huang J and di Sant'Agnese PA: Small cell carcinoma of the prostate. Diagn Histopathol 14: 117-121, 2008.
18. Sasaki T, Komiya A, Suzuki H, et al: Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48: 224-229, 2005.
19. Hansel DE, Nakayama M, Luo J, et al: Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69: 603-609, 2009.
20. Williamson SR, Zhang S, Yao JL, et al: ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 24: 1120-1127, 2011.
21. Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ and Ordonez NG: Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 59: 1803-1809, 1987.
22. Noda K, Nishiwaki Y, Kawahara M, et al; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
23. Deorah S, Rao MB, Raman R, Gaitonde K and Donovan JF: Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. BJU Int 109: 824-830, 2012.